• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

    9/5/24 9:00:00 AM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTX alert in real time by email

    Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform

    Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data

    Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche

    SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024. The Company is developing P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy enriched for stem cell memory T cells (TSCM), in partnership with Roche for the treatment of relapsed/refractory multiple myeloma.

    (PRNewsfoto/Poseida Therapeutics, Inc.)

    "Despite therapeutic advances, multiple myeloma remains an incurable hematologic cancer and relapses are common with BCMA-targeting immunotherapies, such as bispecific T-cell engagers and autologous CAR-T therapies. As a result, patient-focused, off-the-shelf therapies are needed that can provide clinical benefit to patients with relapsed or refractory disease," said Syed Rizvi, M.D., Chief Medical Officer of Poseida Therapeutics. "We look forward to presenting the latest data from our ongoing Phase 1 study of P-BCMA-ALLO1 and its potential as an 'off-the-shelf' therapy for patients at IMS. We are also pleased to announce the initiation of the Phase 1b portion of the study, which will allow us to further explore the promise of this program."

    IMS Oral Presentation

    • Talk Title: OA – 04: A Phase 1 Study of P-BCMA-ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
    • Presenting Author: Bhagirathbhai R. Dholaria, MBBS, Assistant Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
    • Session: Abstract Session 7
    • Presentation Date/Time: Friday, September 27, 2024, at 5:42 PM-5:54 PM local time (4:42 PM ET / 1:42 PM PT)
    • Room: 101 A1-A2

    Company-Hosted IMS Webcast and Conference Call Information:

    Poseida will host a webcast and conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT. The conference call can be accessed by dialing 800-225-9448 or 203-518-9708 (International) with the conference ID PSTX0928. A live webcast may be accessed using the link here, or by visiting the Events and Presentations section of the Poseida website at investors.poseida.com. After the live webcast, the event will remain archived on the Poseida site for approximately 90 days.

    P-BCMA-ALLO1 Phase 1b Clinical Trial

    The Company also announced the initiation of a Phase 1b portion of the ongoing Phase 1 clinical trial of P-BCMA-ALLO1 in patients with multiple myeloma. As a result of achieving this milestone, Poseida will receive a $20 million payment from Roche. Poseida and Roche partnered together on the P-BCMA-ALLO1 Phase 1b trial design, which incorporates process improvements and feedback from recently completed advisory board meetings with leading clinicians. Poseida will continue to have responsibility for the expanded Phase 1/1b trial, which will be funded by Roche.

    About P-BCMA-ALLO1

    P-BCMA-ALLO1 is an allogeneic CAR-T product candidate licensed to Roche targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma. This allogeneic program includes a VH-based binder that targets BCMA and clinical data presented at ASH in December 2023 support the Company's belief that T stem cell (TSCM)-rich allogeneic CAR-Ts have the potential to offer effective, safe, and reliable treatment addressing unmet needs in multiple myeloma. Additional information about the Phase 1 study is available at www.clinicaltrials.gov using identifier: NCT04960579.

    About Poseida Therapeutics, Inc.

    Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

    Forward-Looking Statements 

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected plans with respect to clinical trials, including timing of regulatory and submissions and approvals and clinical data updates; potential fees, reimbursements, milestones, royalty payments and other payments that the Company may receive pursuant to its collaboration agreements with Roche; anticipated timelines and milestones with respect to the Company's development programs and manufacturing activities and capabilities; the potential capabilities and benefits of the Company's technology platforms and product candidates, including the efficacy, safety and tolerability profile of such product candidates; the quote from Dr. Rizvi; and the Company's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's reliance on third parties for various aspects of its business; risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry; the Company's ability to retain key scientific or management personnel; the fact that interim data from the Company's clinical trials may change as more patient data become available and remain subject to audit and verification procedures that could result in material differences from the final data; the fact that subgroup data may differ from future results of the same study once additional data has been received; and the other risks described in the Company's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-new-clinical-data-from-phase-1-study-of-allogeneic-car-t-p-bcma-allo1-in-patients-with-relapsedrefractory-multiple-myeloma-at-21st-international-myeloma-society-annual-meeting-302239426.html

    SOURCE Poseida Therapeutics, Inc.

    Get the next $PSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTX

    DatePrice TargetRatingAnalyst
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    1/4/2023$15.00Buy
    H.C. Wainwright
    1/7/2022$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Poseida Therapeutics Inc.

      15-12G - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/21/25 6:04:42 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.

      SCHEDULE 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      1/13/25 4:05:12 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Poseida Therapeutics Inc.

      EFFECT - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/13/25 12:15:09 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

      SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      11/27/24 7:01:59 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      6/7/24 1:30:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      5/8/24 4:01:24 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Poseida Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Poseida Therapeutics from Overweight to Neutral and set a new price target of $10.00

      12/2/24 10:07:39 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Poseida Therapeutics with a rating of Buy and set a new price target of $15.00

      1/4/23 7:49:53 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Poseida Therapeutics with a rating of Overweight and set a new price target of $24.00

      1/7/22 8:13:46 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Malin Life Sciences Holdings Ltd closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/10/25 4:10:32 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Amado Rafael closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:50 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Corning Luke closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

      Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy

      12/9/24 12:00:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Financials

    Live finance-specific insights

    See more

    $PSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

      Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T

      11/7/24 4:05:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

      Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma who have previously received three or more prior lines of therapy Company to host we

      9/27/24 4:30:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

      Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that

      9/5/24 9:00:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care